Chronic Cough Market Size to Reach USD 9.1 Billion by 2035, Impelled by Rising Prevalence of Respiratory Disease

Chronic Cough Market Outlook 2025-2035:

The 7 major chronic cough market reached a value of USD 5.1 Billion in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 9.1 Billion by 2035, exhibiting a growth rate (CAGR) of 5.49% during 2025-2035. The chronic cough market is advancing rapidly, considering the increasing incidence of respiratory disease awareness, exacerbating air pollution, and age-related factors. The rising chronic conditions such as asthma, COPD, and postnasal drip are resulting in increased demand for effective treatments, while advancements in diagnostic methods along with new medicinal developments are fostering growth in this market. Further expansion of health access in developing nations and the paradigm shift toward tailored treatments is facilitating this market growth. More treatment options and continuous research shall keep this market for chronic cough on an expansion trajectory for many years ahead.

To get more information on this market, Request Sample

Rising Prevalence of Respiratory Disease: Driving the Chronic Cough Market

The main cause driving the chronic cough market forward has been the escalating incidence of respiratory diseases. Today, diseases like asthma, chronic obstructive pulmonary disease, or chronic obstructive pulmonary disease (COPD), and upper respiratory infections are spreading at an alarming rate, particularly due to growing air pollution and smoking along with altered lifestyle. All these diseases generally accompany a chronic cough. It is afflicting millions worldwide; therefore, effective drugs are being searched for the increasingly large pool of patients. Presently, the menace of respiratory diseases is becoming a cause for concern. Of late, most parts of the urban population have been suffering from chronic cough due to increasing pollution in cities. The prospects of aging people are growing over the years, and it always leaves them vulnerable to falling prey to such respiratory problems. Alongside this, the increasing consciousness and diagnosis of these conditions have further driven market growth because patients are seeking treatments for chronic cough. As research and medical studies advance, the chronic cough market is increasing steadily where more attention is given to dealing with respiratory diseases.

Development of Novel Therapies and Pharmacological Treatments: Contributing to Market Expansion

The development of new therapies and pharmacological treatments for chronic cough is a major driver for the growth of the market, since chronic cough is increasingly recognized as a separate medical condition that greatly impacts patients' quality of life. Chronic cough is when cough occurs for more than eight weeks and may have its origin from various factors associated with asthma, allergies, acid reflux (GERD), and respiratory infections. The most formidable challenge in the treatment of chronic cough lies in the lack of visible causes at times. New treatments targeting the underlying mechanism of chronic cough, including drugs which act to interrupt neural pathways responsible for the cough reflex, are currently being designed. Some emerging drugs in this direction include neuromodulators and receptor blockers, which could potentially be more targeted as opposed to nonspecific cough syrups or decongestants. New biologic treatments aim at reducing inflammation and controlling cough reflexes. Current research is now geared towards the specific diseases, such as chronic cough with idiopathic chronic cough that occurs without any obvious cause. Advances in knowledge on molecular mechanisms of chronic cough have, in turn led to more sophisticated treatment options. Combination therapies, targeting more than one trigger of chronic cough, are also under investigation in clinical trials and yielding positive results. As regulatory agencies recognize the necessity for targeted treatments, the pipeline for approval of chronic cough therapies is expanding. More investments into research and development along with growing patients, in addition to proper awareness about the seriousness of the condition being chronic cough and thus being properly addressed by medicine, have contributed significantly towards this widened market for treatment therapies.

Emerging Therapies in Chronic Cough Market

AX-8: Axalbion

AX-8 (Axalbion) is a medication that has been specifically designed to treat chronic cough. It helps alleviate persistent coughing by addressing the root causes of irritation in the respiratory tract. The formulation works to reduce inflammation and soothe the throat, offering relief from the discomfort associated with long-term coughs, and improving overall respiratory function.

ADX-629: Aldeyra Therapeutics

ADX-629 is an investigational oral treatment developed by Aldeyra Therapeutics aimed at addressing chronic cough. It targets reactive aldehyde species (RASP) to help reduce airway inflammation and irritation. Initial clinical studies have indicated that ADX-629 significantly lowers cough frequency, presenting a promising new solution for those struggling with chronic cough.

Nalbuphine extended release: Trevi Therapeutics

Nalbuphine extended release is a novel opioid analgesic formulation of Trevi Therapeutics, which is specifically designed for the treatment of chronic cough. An extended-release formulation would ensure a prolonged sustainable relief through the cough reflex pathway, possibly giving a more controlled and prolonged action than the immediate-release formulations. Nalbuphine ER aims to significantly reduce the severity and frequency of chronic cough, with minimal potential for abuse or side effects typical of opioids by exploiting the agonist and antagonist effects of nalbuphine at opioid receptors.

Detailed list of emerging therapies in Chronic Cough is provided in the final report…

Leading Companies in the Chronic Cough Market:

The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global chronic cough market, several leading companies are at the forefront of developing integrated platforms to enhance the management of chronic cough. Some of the major players include Bayer, Merck, and others. These companies are driving innovation in the chronic cough market through continuous research, diagnostic tools, and expanding their product offerings to meet the growing demand for chronic cough.

Recent advancements in the treatment of chronic cough include gefapixant, an oral medication still under investigation. It is specifically an antitussive drug designed to target P2X3 receptors that mediate hypersensitivity due to the cough reflex. Clinical trials have shown gefapixant to reduce both frequency and severity of coughing in patients with refractory chronic cough. A meta-analysis showed that administration of gefapixant at 45 mg twice daily reduced coughing bouts during wakefulness by 17.6% compared with a placebo. Additionally, the results of an article in The Lancet stated that some patients with chronic cough experienced improvement of their symptoms up to 60% due to gefapixant. These results make gefapixant a potential candidate to be used for patients suffering from chronic cough, especially those that have not found relief with other treatments.

Key Players in Chronic Cough Market:

The key players in the Chronic Cough market who are in different phases of developing different therapies are Axalbion, Shionogi, Aldeyra Therapeutics, Trevi Therapeutics, Bayer, Merck, and Others.

Regional Analysis:

The major markets for chronic cough include the United States, Germany, France, the United Kingdom, Italy, Spain, and Japan. According to projections by IMARC, the United States has the largest patient pool for chronic cough while also representing the biggest market for its treatment. Recent developments in the management of chronic cough have emphasized targeted therapies to address underlying neuropathic mechanisms. New biological treatments are under investigation for inflammation and specific immune system factors, especially in asthma and COPD. Novel antitussive approaches that target specific receptors involved in the cough reflex have been promising in clinical trials. These treatments are for the reduction in frequency and severity of chronic cough. It improves quality of life of patients.

Recent Developments in Chronic Cough Market:

• In October 2024, Trevi Therapeutics reported the completion of patient enrollment in the Phase 2a clinical study for Haduvio (oral nalbuphine ER), which is currently being investigated for refractory chronic cough (RCC). This multi-center, investigator-initiated, and open-label trial was conducted across multiple clinical sites in the U.K. and Canada and involved approximately 60 participants. The research will evaluate safety, efficacy, and optimal dosing of Haduvio. Results from the study are expected to be published in the first quarter of 2025.
• In August 2024, the company Axalbion disclosed that the first patient has been administered treatment in the second part of its Phase 2 clinical study for chronic cough, which was announced as a randomized, placebo-controlled study using the company's lead compound, AX-8. The AX-8 drug is an oral, powerful, and selective drug for the TRPM8 ion channel associated with multiple sensory processes. To support the conduct of the ongoing trial and preparation for a Phase 3 trial, Axalbion has already secured the requisite additional funding from existing investors as well as new investors.
• In June 2023, Aldeyra Therapeutics shared promising top-line results from a Phase 2 clinical trial of ADX-629, an experimental oral treatment, for chronic cough. The study showed a significant decrease in cough frequency in patients who received ADX-629 compared to those who were given a placebo.

Key information covered in the report

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

 Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic cough market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic cough market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report offers a comprehensive analysis of current chronic cough marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

 Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. Across the six major continents and 100+ countries, we work alongside our business partners as one team with a common ambition to achieve unparallelled results, gain a competitive edge, and transform industries. IMARC Group excels in understanding its clients’ business priorities and delivering tailored solutions that drive meaningful outcomes. Our client base spans over 3,000 organizations in the private, public, and social sectors, ranging from high-growth startups to Fortune 500 companies.

Contact Us:

IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800